zika
viru
zikv
infect
pregnant
women
lead
fetal
death
malform
previous
report
zikv
envelop
protein
domain
iii
ediii
subunit
vaccin
candid
crossneutr
activ
howev
like
mani
subunit
vaccin
efficaci
limit
improv
efficaci
subunit
vaccin
identifi
nonneutr
epitop
zikv
ediii
surround
residu
buri
fulllength
envelop
protein
becom
expos
recombin
ediii
shield
epitop
engin
glycan
probe
compar
wildtyp
ediii
mutant
ediii
induc
significantli
stronger
neutral
antibodi
three
mous
strain
also
demonstr
significantli
improv
efficaci
fulli
protect
mice
particularli
pregnant
mice
fetus
highdos
lethal
zikv
challeng
moreov
mutant
ediii
immun
sera
significantli
enhanc
passiv
protect
efficaci
fulli
protect
mice
lethal
zikv
challeng
passiv
protect
posit
associ
neutral
antibodi
titer
show
enhanc
efficaci
mutant
ediii
due
shield
immunodomin
nonneutr
epitop
surround
residu
led
immun
refocus
neutral
epitop
taken
togeth
result
studi
reveal
intrins
limit
subunit
vaccin
artifici
expos
immunodomin
nonneutr
epitop
overcom
glycan
shield
addit
mutant
zikv
protein
gener
studi
promis
subunit
vaccin
candid
high
efficaci
prevent
zikv
infect
mice
import
viral
subunit
vaccin
gener
show
low
efficaci
studi
reveal
intrins
limit
subunit
vaccin
design
artifici
expos
surfac
subunit
vaccin
contain
epitop
unfavor
vaccin
efficaci
specif
identifi
epitop
zika
viru
zikv
envelop
protein
domain
iii
ediii
buri
fulllength
envelop
protein
becom
expos
recombin
ediii
shield
epitop
glycan
result
mutant
ediii
vaccin
demonstr
significantli
enhanc
efficaci
wildtyp
ediii
vaccin
protect
anim
model
zikv
infect
therefor
intrins
limit
subunit
vaccin
overcom
shield
artifici
expos
unfavor
epitop
engin
ediii
vaccin
gener
studi
promis
vaccin
candid
develop
battl
zikv
infect
diseas
syndrom
congenit
zika
syndrom
symptom
includ
microcephali
brain
abnorm
congenit
malform
although
sever
zikv
vaccin
current
clinic
trial
vaccin
approv
fda
use
human
genom
zikv
singlestrand
positivesens
rna
encod
number
structur
nonstructur
protein
envelop
e
protein
major
structur
protein
guid
viral
entri
host
cell
first
bind
host
receptor
fuse
viral
host
membran
anchor
viral
envelop
form
dimer
monom
contain
multipl
structur
domain
domain
edi
domain
ii
edii
domain
iii
ediii
stem
region
transmembran
domain
tm
e
protein
main
induc
host
immun
respons
fulllength
e
protein
individu
domain
prime
target
subunit
vaccin
design
among
domain
edi
edii
ediii
trigger
antibodyenhanc
zikv
entri
ediii
play
critic
role
viral
entri
bind
host
receptor
safeti
ediii
focu
subunit
vaccin
develop
previous
show
zikv
ediiibas
recombin
subunit
vaccin
effect
elicit
longterm
broadspectrum
neutral
antibodi
diverg
zikv
strain
howev
efficaci
optim
improv
efficaci
subunit
vaccin
key
potenti
contribut
prevent
zikv
infect
recombin
subunit
vaccin
better
safeti
attenu
viral
vaccin
unlik
attenu
vaccin
subunit
vaccin
contain
residu
infect
howev
subunit
vaccin
often
show
insuffici
efficaci
structurebas
vaccin
design
intens
pursu
improv
efficaci
subunit
vaccin
aid
battl
variou
viral
diseas
vaccin
design
envelop
protein
hiv
influenza
viru
nonzikv
flavivirus
modifi
preserv
specif
neutral
epitop
subtract
mask
epitop
potenti
induc
antibodydepend
enhanc
effect
unfavor
immun
respons
tri
understand
gener
low
efficaci
viral
subunit
vaccin
recent
identifi
intrins
limit
recombin
subunit
vaccin
use
middl
east
respiratori
syndrom
mer
coronaviru
merscov
model
system
subunit
vaccin
part
larg
viral
envelop
protein
viru
particl
henc
much
surfac
area
buri
howev
recombin
subunit
vaccin
made
previous
buri
surfac
area
becom
artifici
expos
contain
immunodomin
nonneutr
epitop
distract
host
immun
system
react
neutral
epitop
also
develop
neutral
immunogen
index
nii
quantit
character
contribut
epitop
overal
immunogen
subunit
vaccin
spite
initi
success
merscov
subunit
vaccin
design
concept
intrins
limit
viral
subunit
vaccin
strategi
use
nii
quantit
character
epitop
extend
subunit
vaccin
design
target
anoth
viru
studi
analyz
tertiari
structur
zikv
ediii
identifi
artifici
expos
epitop
vaccin
surfac
shield
glycan
probe
character
nii
measur
efficaci
mutant
ediii
protect
mice
fetus
zikv
infect
investig
molecular
mechan
enhanc
efficaci
mutant
ediii
overal
studi
firmli
establish
character
intrins
limit
viral
subunit
vaccin
point
way
overcom
limit
import
implic
design
develop
novel
viral
subunit
vaccin
mutant
zikv
ediii
gener
studi
promis
subunit
vaccin
candid
prevent
zikv
infect
human
identif
mask
nonneutr
epitop
zikv
ediii
identifi
potenti
immunodomin
nonneutr
epitop
zikv
ediii
analyz
crystal
structur
zikv
e
protein
dimer
pdb
identifi
id
found
patch
surfac
area
ediii
buri
fulllength
e
protein
dimer
becom
expos
recombin
ediii
locat
center
patch
protrud
bent
fig
b
henc
engin
glycan
probe
onto
epitop
surround
residu
ie
epitop
fig
end
introduc
doubl
mutat
ediii
chang
residu
nlink
glycosyl
site
express
purifi
mutant
ediii
along
wildtyp
ediii
mammalian
cell
protein
contain
ctermin
fc
tag
purifi
homogen
result
western
blot
show
protein
ran
dimer
without
boil
due
fc
dimer
tag
incomplet
denatur
monom
boil
due
complet
denatur
mutant
ediii
ran
slower
slightli
larger
molecular
weight
wildtyp
ediii
fig
indic
mutant
ediii
glycosyl
addit
glycan
probe
residu
character
conform
mutant
zikv
ediii
investig
bind
interact
zikv
ediii
wild
type
mutant
ediiispecif
monoclon
antibodi
mab
use
enzymelink
immunosorb
assay
elisa
among
mab
use
studi
shown
previous
potent
neutral
zikv
infect
mice
andor
vitro
wherea
neutral
activ
vitro
vitro
activ
character
use
plaquebas
neutral
assay
fig
result
show
mutant
ediii
bound
bind
comparison
wildtyp
ediii
bound
six
mab
fig
crystal
structur
zikv
e
protein
complex
sever
mab
determin
previous
group
base
previous
determin
structur
analyz
bind
site
mab
ediii
crystal
structur
zikv
e
protein
complex
zikv
ediii
complex
reveal
bind
area
expos
e
protein
dimer
like
receptorbind
site
wherea
bind
area
center
epitop
buri
e
protein
dimer
becom
artifici
expos
recombin
ediii
fig
structur
analysi
ediii
complex
identifi
later
ridg
away
epitop
ediii
recogn
epitop
structur
base
bind
known
mab
may
also
bind
function
import
region
ediii
away
epitop
overal
data
confirm
mutant
ediii
success
incorpor
glycan
residu
block
bind
nonneutr
mab
also
reveal
despit
introduc
glycan
mutant
ediii
retain
nativ
structur
conform
antigen
bind
five
differ
neutral
mab
measur
neutral
immunogen
index
ediii
epitop
previous
defin
neutral
immunogen
index
nii
epitop
contribut
epitop
overal
neutral
immunogen
vaccin
epitop
zikv
ediii
nii
calcul
differ
neutral
immunogen
wildtyp
ediii
mutant
ediii
divid
neutral
immunogen
wildtyp
ediii
measur
nii
epitop
zikv
ediii
immun
mice
wildtyp
ediii
mutant
ediii
individu
measur
neutral
antibodi
titer
induc
sera
immun
mice
includ
immunocompet
balbc
mice
well
immunocompromis
receptor
ifnar
defici
mice
background
result
show
compar
wildtyp
ediii
mutant
ediii
induc
significantli
higher
titer
antizikv
neutral
antibodi
fig
c
similar
titer
zikv
ediiispecif
igg
antibodi
three
type
immun
mice
fig
f
data
suggest
epitop
make
neg
contribut
overal
neutral
immunogen
ediii
furthermor
mask
epitop
affect
total
igg
antibodi
product
instead
increas
overal
neutral
immunogen
vaccin
also
calcul
nii
epitop
valu
nii
vari
slightli
differ
mice
balbc
mice
fig
neg
nii
confirm
neg
contribut
epitop
overal
neutral
immunogen
vaccin
valu
nii
suggest
mask
epitop
increas
overal
neutral
immunogen
vaccin
calcul
use
formula
prnt
prnt
prnt
prnt
plaqu
reduct
neutral
titer
wild
type
respect
balbc
mice
therefor
data
reveal
epitop
immunodomin
nonneutr
epitop
mask
significantli
improv
neutral
immunogen
ediii
vaccin
investig
differ
antigen
dose
affect
neutral
immunogen
mutant
zikv
ediii
vaccin
balbc
mice
divid
six
group
group
immun
one
three
dose
gmous
either
wildtyp
mutant
vaccin
induc
igg
neutral
antibodi
compar
result
show
dose
test
wildtyp
mutant
ediii
vaccin
induc
amount
igg
antibodi
titer
fig
mutant
ediii
elicit
significantli
higher
titer
antizikv
neutral
antibodi
wildtyp
ediii
fig
addit
vaccin
dose
posit
associ
mice
immun
wildtyp
wt
mutant
zikv
ediii
vaccin
sera
collect
day
immun
detect
neutral
antibodi
zikv
strain
use
plaqu
reduct
neutral
test
c
igg
antibodi
f
pb
includ
control
neutral
activ
express
plaqu
reduct
neutral
antibodi
titer
prnt
data
present
mean
prnt
sem
quadrupl
well
serial
dilut
sera
pool
mice
group
signific
differ
wt
mutant
ediii
protein
shown
p
p
igg
antibodi
titer
express
endpoint
dilut
remain
posit
detect
g
measur
neutral
immunogen
index
nii
mutant
ediii
protein
use
serum
neutral
antibodi
titer
prnt
balbc
mice
describ
nii
valu
calcul
base
formula
prnt
prnt
prnt
prnt
prnt
repres
prnt
neutral
antibodi
titer
wildtyp
mutant
ediii
protein
respect
separ
experi
balbc
mice
immun
differ
dose
wt
mutant
zikv
ediii
protein
sera
collect
day
immun
detect
igg
h
neutral
antibodi
zikv
strain
describ
igg
antibodi
titer
express
endpoint
dilut
remain
posit
detect
neutral
antibodi
titer
express
prnt
data
present
mean
sem
quadrupl
well
serial
dilut
sera
pool
mice
group
experi
repeat
three
time
similar
result
obtain
induc
neutral
antibodi
titer
fig
data
suggest
immun
increas
dose
epitop
ediii
potenti
improv
overal
neutral
immunogen
vaccin
identifi
predomin
igg
subtyp
also
investig
whether
epitop
mask
affect
subtyp
product
sera
balbc
mice
immun
wildtyp
mutant
ediii
protein
evalu
igg
subtyp
content
result
show
predomin
subtyp
induc
vaccin
mous
strain
fig
hand
low
titer
detect
mice
fig
low
titer
detect
mice
fig
low
titer
detect
balbc
mice
fig
low
titer
detect
mous
strain
test
fig
overal
compar
wildtyp
ediii
mutant
ediii
induc
andor
subtyp
mous
strain
result
demonstr
although
total
igg
titer
similar
mice
immun
wildtyp
mutant
ediii
vaccin
associ
igg
subtyp
vari
depend
mous
strain
test
enhanc
efficaci
mutant
ediii
vaccin
protect
mice
fetus
investig
efficaci
mutant
zikv
ediii
vaccin
protect
immunocompet
pregnant
mice
fetus
zikv
infect
immunocompet
adult
mice
balbc
nonleth
model
zikv
infect
end
immun
balbc
mice
either
wildtyp
mutant
ediii
vaccin
challeng
pregnant
mice
zikv
collect
placenta
fetal
brain
day
postchalleng
measur
titer
rna
copi
zikv
sampl
respect
use
plaqu
quantit
revers
transcriptionpcr
qrtpcr
assay
embryo
also
collect
comparison
fetal
statu
result
show
contrast
wildtypeediiitr
group
mutantediiiimmun
pregnant
mice
undetect
viral
titer
rna
copi
placenta
fetal
brain
fig
b
negativecontrol
pregnant
mice
treat
phosphatebuff
salin
pb
contain
significantli
higher
viral
titer
rna
copi
tissu
fig
fig
igg
subtyp
antibodi
induc
wildtyp
mutant
zikv
ediii
vaccin
balbc
mice
immun
wildtyp
mutant
ediii
protein
vaccin
sera
collect
day
immun
detect
igg
subtyp
antibodi
e
specif
target
zikv
ediii
protein
pb
includ
control
antibodi
titer
express
form
endpoint
titer
calcul
reciproc
highest
detect
dilut
data
present
mean
sem
mice
group
n
experi
repeat
three
time
similar
result
obtain
p
wildtyp
mutant
ediii
vaccin
b
addit
signific
morpholog
chang
uteri
wildtypeand
mutantediiiimmun
pregnant
mice
embryo
mice
good
condit
contrast
pbstreat
mice
show
sever
resorpt
uteri
embryo
mice
invis
fig
collect
compar
wildtyp
ediii
vaccin
mutant
ediii
vaccin
provid
enhanc
efficaci
protect
immunocompet
pregnant
mice
zikv
infect
evidenc
undetect
viral
titer
rna
copi
although
wildtyp
mutant
ediii
vaccin
protect
fetus
immunocompet
pregnant
mice
zikv
infect
also
evalu
efficaci
mutant
zikv
ediii
vaccin
protect
immunocompromis
mice
fetus
zikv
infect
immunocompromis
mice
lethal
model
zikv
infect
end
immun
femal
male
mice
either
wildtyp
mutant
zikv
ediii
vaccin
treat
femal
male
mice
differ
first
challeng
immun
femal
pregnant
mice
zikv
collect
tissu
includ
placenta
fetal
brain
day
postchalleng
measur
zikv
titer
tissu
use
plaqu
assay
also
examin
embryo
uteri
day
postchalleng
result
show
compar
wildtypeediiitr
group
mutantediiiimmun
femal
pregnant
mice
significantli
lower
viral
titer
lung
liver
heart
muscl
fig
placenta
undetect
viral
titer
fetal
brain
fig
signific
morpholog
chang
uteri
moreov
embryo
good
condit
wildtypeand
mutantediiitr
mice
fig
negativecontrol
group
ie
pbstreat
femal
pregnant
mice
viral
titer
high
test
tissu
fetal
brain
signific
morpholog
chang
uteri
sever
fetal
resorpt
fetal
death
fig
second
challeng
adult
male
mice
lowdos
pfu
highdos
pfu
zikv
sequenti
observ
surviv
weight
chang
result
show
male
mice
immun
either
wildtyp
mutant
ediii
vaccin
challeng
lowdos
zikv
surviv
day
challeng
fig
weight
decreas
slightli
day
postinfect
kept
increas
steadili
afterward
fig
contrast
negativecontrol
group
ie
pbstreat
mice
mice
pregnant
mice
challeng
zikv
stain
pfu
detect
viral
titer
viral
rna
placenta
fetal
brain
use
plaqu
quantit
revers
transcriptas
pcr
qrtpcr
b
assay
day
challeng
error
bar
indic
sem
n
p
detect
limit
plaqu
assay
pfug
qrtpcr
rna
copiesg
tissu
c
morpholog
uteri
embryo
immun
pregnant
balbc
mice
day
zikv
challeng
least
weight
loss
human
euthan
day
postinfect
fig
b
moreov
mutantediiiimmun
mice
surviv
second
highdos
zikv
challeng
surviv
obviou
weight
loss
contrast
wildtypeediiiimmun
mice
surviv
second
highdos
zikv
challeng
consider
weight
loss
day
postchalleng
fig
furthermor
neutral
antibodi
titer
mutantediiiimmun
mice
significantli
higher
wildtypeediiiimmun
mice
challeng
particularli
challeng
fig
therefor
enhanc
protect
efficaci
mutant
ediii
vaccin
highdos
zikv
challeng
like
due
higher
serum
neutral
antibodi
titer
induc
overal
data
reveal
mutant
ediii
vaccin
protect
immunocompromis
femal
pregnant
mice
fetus
zikv
infect
effect
wildtyp
ediii
vaccin
evidenc
undetect
significantli
reduc
viral
titer
also
protect
immunocompromis
adult
male
mice
highdos
zikv
infect
effect
evidenc
improv
surviv
rate
steadili
maintain
weight
enhanc
passiv
protect
efficaci
mutantzikvediiiinduc
mous
sera
understand
associ
enhanc
protect
efficaci
mutant
ediii
vaccin
increas
neutral
antibodi
titer
induc
passiv
protect
experi
perform
use
wildtyp
mutantediiiinduc
mous
sera
end
sera
pool
group
normal
equal
ediiispecif
igg
titer
adult
mice
passiv
transfer
pool
sera
either
undilut
dilut
mice
challeng
zikv
viremia
surviv
rate
weight
chang
subsequ
monitor
result
show
viremia
significantli
lower
mice
passiv
transfer
mutantediiiinduc
sera
transfer
wildtypeediiiinduc
sera
fig
addit
mice
transfer
dilut
mutantediiiinduc
sera
surviv
zikv
challeng
mice
transfer
undilut
sera
surviv
zikv
challeng
surviv
show
slight
pregnant
mice
challeng
zikv
strain
pfu
test
viral
titer
use
plaqu
assay
differ
tissu
includ
lung
liver
heart
muscl
placenta
fetal
brain
b
day
postchalleng
error
bar
indic
sem
n
p
respect
detect
limit
lung
heart
pfug
liver
muscl
placenta
fetal
brain
pfug
tissu
c
morpholog
uteri
embryo
immun
pregnant
mice
day
zikv
challeng
describ
arrow
indic
fetal
death
weight
loss
fig
c
comparison
mice
transfer
dilut
undilut
wildtypeinduc
sera
surviv
rate
significantli
lower
lower
dilut
undilut
mutantediiiinduc
sera
respect
former
group
also
signific
weight
loss
day
postchalleng
fig
c
moreov
mutantediiiinduc
sera
significantli
higher
antizikv
neutral
antibodi
titer
wildtypeediiiinduc
sera
fig
negativecontrol
mice
transfer
pbsinduc
sera
surviv
rate
day
postchalleng
also
highest
viral
titer
weight
loss
fig
surviv
mice
wt
mutant
group
challeng
zikv
pfu
observ
surviv
c
weight
describ
n
percent
weight
panel
b
repres
mean
percent
weight
surviv
mice
indic
day
challeng
error
bar
indic
sem
e
neutral
antibodi
sera
mice
challeng
challeng
zikv
strain
plaqu
reduct
neutral
assay
data
express
mean
prnt
sem
quadrupl
well
serial
dilut
sera
pool
mice
group
experi
repeat
three
time
similar
result
obtain
character
protect
efficaci
passiv
transfer
sera
mutantzikvediiivaccineimmun
mice
mice
passiv
transfer
mutant
ediiiimmun
mous
sera
six
hour
later
challeng
zikv
strain
pfu
follow
evalu
serum
viral
titer
day
postchalleng
well
surviv
weight
chang
day
mous
sera
wtediiior
pbsimmun
mice
includ
control
zikv
titer
sera
challeng
mice
collect
day
zikv
challeng
error
bar
indic
sem
n
p
respect
detect
limit
pfuml
sera
surviv
b
weight
c
rate
serum
transfer
mice
zikv
challeng
also
record
error
bar
indic
sem
n
panel
b
p
wt
mutant
ediii
protein
group
dilut
percent
weight
panel
c
repres
mean
percent
weight
surviv
mice
day
indic
challeng
character
neutral
antibodi
sera
zikv
challeng
use
plaqu
reduct
neutral
test
neutral
activ
express
prnt
error
bar
indic
sem
n
p
respect
experi
repeat
three
time
similar
result
obtain
data
indic
compar
wildtypeediiiinduc
sera
mutantediiiinduc
sera
contain
significantli
higher
neutral
antibodi
titer
well
significantli
enhanc
passiv
protect
efficaci
zikv
challeng
like
posit
associ
molecular
mechan
enhanc
efficaci
mutant
ediii
explor
molecular
mechan
enhanc
efficaci
mutant
ediii
vaccin
examin
competit
bind
among
ediii
ediiispecif
mab
ediiiinduc
sera
use
elisa
specif
investig
bind
interact
wildtyp
ediii
ediiispecif
neutral
mab
presenc
mutantediiiinduc
mous
sera
wildtypeediiiinduc
mous
sera
use
comparison
result
show
compar
wildtypeediiiinduc
mous
sera
mutantediiiinduc
sera
immunocompet
balbc
mice
fig
immunocompromis
mice
fig
h
block
bind
wildtyp
ediii
ediiispecif
neutral
mab
effect
show
earlier
wildtyp
mutant
ediii
vaccin
induc
similar
titer
total
igg
antibodi
fig
result
competit
bind
assay
suggest
mutant
ediii
vaccin
induc
higher
neutral
antibodi
titer
wildtyp
ediii
vaccin
therefor
mask
immunodomin
nonneutr
epitop
ie
nii
neg
rel
larg
absolut
valu
trigger
host
immun
system
refocu
neutral
less
immunodomin
epitop
ie
nii
posit
rel
small
absolut
valu
account
product
neutral
antibodi
zikv
pose
signific
threat
human
health
particularli
acquir
capabl
cross
placenta
infect
pregnant
women
fetus
lead
sever
consequ
fetal
neuropatholog
fetal
death
develop
safe
effect
vaccin
protect
pregnant
women
fetus
high
prioriti
biomed
field
date
number
vaccin
candid
test
mous
nonhuman
primat
model
zikv
infect
vaccin
candid
current
clinic
trial
contrast
tradit
vaccin
typic
focu
inactiv
attenu
viru
particl
subunit
vaccin
contain
antigen
compon
pathogen
henc
gener
safer
stabl
tradit
vaccin
http
wwwwhoint
zikv
e
protein
guid
viral
entri
cell
main
induc
host
immun
respons
shown
unlik
domain
e
protein
recombin
zikv
ediii
induc
antibodyenhanc
viral
entri
henc
safe
subunit
vaccin
protect
mice
zikv
challeng
howev
like
mani
recombin
subunit
vaccin
zikv
ediii
show
follow
intrins
limit
affect
protect
efficaci
domain
zikv
e
protein
ediii
larg
surfac
area
buri
fulllength
dimer
e
protein
express
individu
recombin
ediii
previous
buri
surfac
area
becom
artifici
expos
artifici
expos
surfac
area
ediii
may
contain
immunodomin
nonneutr
epitop
distract
host
immun
system
react
neutral
epitop
eg
epitop
receptorbind
region
studi
aim
overcom
intrins
limit
zikv
ediii
first
identifi
artifici
expos
epitop
zikv
ediii
around
residu
introduc
glycan
cover
epitop
ie
epitop
goal
shield
epitop
host
immun
system
forc
host
immun
system
refocu
neutral
epitop
receptorbind
region
character
mutant
zikv
ediii
epitop
shield
like
wildtyp
ediii
mutant
ediii
bound
ediiispecif
neutral
mab
receptorbind
region
suggest
mutant
ediii
retain
natur
conform
howev
wildtyp
ediii
mutant
ediii
bound
ediiispecif
nonneutr
mab
target
epitop
indic
epitop
success
glycosyl
mutant
ediii
increas
molecular
weight
mutant
ediii
also
confirm
success
glycosyl
epitop
measur
neutral
immunogen
index
nii
sever
mous
strain
nii
epitop
differ
mous
strain
neg
suggest
epitop
make
neg
contribut
overal
neutral
immunogen
ediii
vaccin
nii
epitop
differ
mous
strain
vari
suggest
shield
epitop
increas
overal
neutral
immunogen
particularli
absolut
valu
nii
epitop
lower
mice
balbc
mice
suggest
shield
epitop
increas
overal
neutral
immunogen
immunocompromis
mice
less
immunocompet
balbc
mice
moreov
neutral
immunogen
epitop
mutant
ediii
vaccin
increas
vaccin
dose
examin
efficaci
mutant
ediii
protect
mice
zikv
challeng
compar
wildtyp
ediii
vaccin
mutant
ediii
vaccin
protect
femal
pregnant
mice
immunocompet
immunocompromis
mice
fetus
effect
also
improv
surviv
rate
immunocompromis
male
mice
highdos
lethal
zikv
challeng
addit
mutantediiiimmun
mous
sera
passiv
protect
mice
effect
wildtypeediiiimmun
mous
sera
lethal
zikv
challeng
protect
posit
associ
serum
neutral
antibodi
titer
investig
molecular
mechan
behind
enhanc
efficaci
mutant
ediii
vaccin
found
shield
epitop
significantli
increas
neutral
antibodi
titer
maintain
similar
total
igg
antibodi
titer
immun
mice
henc
shield
immunodomin
nonneutr
epitop
forc
host
immun
system
refocu
neutral
epitop
subunit
vaccin
studi
flavivirus
tickborn
enceph
viru
tbev
suggest
may
variat
specif
antibodi
respons
includ
neutral
antibodi
respons
immun
mice
immun
vaccin
virusinfect
human
mice
antibodi
respons
mainli
target
ediii
human
antibodi
respons
mainli
target
ediedii
clear
whether
case
zikv
vaccin
nevertheless
caution
taken
design
ediiibas
zikv
subunit
vaccin
human
use
worth
note
adjuv
play
import
role
potenti
subunit
vaccineinduc
immun
respons
includ
neutral
antibodi
aluminum
hydroxid
adjuv
may
enhanc
overal
immun
respons
modul
specif
function
activ
antibodi
respons
induc
ediiibas
tbev
vaccin
mice
adjuv
system
combin
monophosphoryl
lipid
mpl
aluminum
salt
licens
use
human
vaccin
eg
human
papillomaviru
hepat
b
viru
vaccin
increas
antibodi
titer
compar
aluminum
adjuv
hydroxid
salt
alon
combin
mpl
aluminum
salt
may
induc
isotypeswitch
igg
antibodi
respons
significantli
elev
total
igg
neutral
antibodi
induc
subunit
vaccin
accept
safeti
profil
inde
studi
found
aluminum
hydroxid
mpl
adjuv
combin
elicit
hightit
neutral
antibodi
conjug
wildtyp
mutant
zikv
ediii
vaccin
addit
compar
recombin
protein
vaccin
target
ediii
flavivirus
freund
adjuv
wildtyp
zikv
ediii
vaccin
aluminum
hydroxid
mpl
adjuv
combin
seem
induc
higher
titer
neutral
antibodi
gener
demonstr
studi
vaccin
target
zikv
ediii
elicit
high
igg
antibodi
titer
rel
low
neutral
antibodi
titer
henc
justifi
use
adjuv
consist
previou
data
zikv
ediii
vaccin
elicit
potent
subtyp
antibodi
respons
mous
strain
test
suggest
antibodi
subtyp
might
associ
neutral
antibodi
product
also
found
aluminum
hydroxid
mpl
adjuv
combin
help
induct
balbc
mice
subtyp
mice
result
balanc
immun
respons
futur
studi
need
compar
immunogen
zikv
ediii
vaccin
wild
type
mutant
presenc
aluminum
hydroxid
mpl
adjuv
combin
aluminum
hydroxid
alon
mpl
alon
determin
whether
enhanc
immunogen
associ
adjuvant
combin
adjuv
studi
also
help
compar
immunogen
efficaci
vaccin
previou
ediiibas
zikv
flaviviru
vaccin
use
differ
adjuv
sum
studi
second
success
applic
concept
nii
vaccin
design
first
applic
mer
coronaviru
subunit
vaccin
design
studi
establish
follow
import
principl
subunit
vaccin
design
first
artifici
expos
region
viral
subunit
vaccin
contain
immunodomin
nonneutr
epitop
second
epitop
limit
efficaci
viral
subunit
vaccin
distract
host
immun
system
react
neutral
epitop
third
shield
epitop
improv
efficaci
vaccin
refocus
host
immun
system
neutral
epitop
principl
potenti
extend
mani
viral
subunit
vaccin
vaccin
influenza
ebola
virus
studi
also
produc
safe
highli
effect
zikv
subunit
vaccin
hold
promis
develop
success
vaccin
protect
pregnant
women
fetus
therefor
current
studi
import
implic
battl
zikv
vaccin
design
gener
anim
femal
balbc
mice
male
femal
mice
use
studi
mice
breed
pair
background
origin
purchas
jackson
laboratori
maintain
selfbreed
anim
facil
anim
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
protocol
approv
institut
anim
care
use
committe
iacuc
new
york
blood
center
permit
number
recombin
zikv
ediii
protein
prepar
previous
describ
briefli
zikv
ediii
protein
contain
residu
ie
wild
type
construct
base
zikv
e
strain
genbank
access
number
fuse
ctermin
human
fc
tag
mutant
zikv
ediii
protein
contain
glycan
probe
surround
residu
ie
construct
multisit
mutagenesi
kit
thermo
fisher
scientif
use
wildtyp
ediii
plasmid
templat
recombin
protein
transient
express
cell
cultur
supernat
purifi
protein
affin
chromatographi
ge
healthcar
anim
immun
purifi
zikv
ediii
vaccin
wild
type
mutant
use
immun
mice
previous
describ
briefli
group
six
balbc
mice
intramuscularli
im
immun
ediii
vaccin
wildtyp
mutant
gmous
pb
control
plu
combin
aluminum
hydroxid
adjuv
g
mous
invivogen
monophosphoryl
lipid
mpl
adjuv
gmous
vacmpla
invivogen
immun
mice
boost
immunogen
week
sera
collect
day
postlast
immun
test
antibodi
respons
neutral
antibodi
addit
group
five
balbc
mice
week
old
immun
boost
ediii
vaccin
wild
type
mutant
gmous
respect
presenc
aluminum
hydroxid
mpl
adjuv
combin
follow
detect
igg
neutral
antibodi
describ
western
blot
purifi
protein
analyz
use
western
blot
previous
describ
briefli
protein
first
run
trisglycin
sdspage
gel
transfer
nitrocellulos
membran
western
blot
analysi
transfer
blot
block
fatfre
milk
pbstween
pbst
overnight
follow
sequenti
incub
zikv
ehi
proteinimmun
mous
sera
laboratori
stock
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
h
room
temperatur
signal
visual
ecl
western
blot
substrat
buffer
amersham
hyperfilm
ge
healthcar
elisa
bind
interact
zikv
ediii
protein
ediiispecif
mab
character
use
elisa
previous
describ
mab
includ
mous
mab
bei
resourc
well
human
mab
absolut
antibodi
briefli
elisa
plate
coat
wildtyp
mutant
zikv
ediii
protein
overnight
block
fatfre
milk
pbst
h
three
wash
plate
sequenti
incub
serial
dilut
mab
hrpconjug
antimous
iggfab
thermo
fisher
scientif
antihuman
iggfab
abcam
antibodi
h
reaction
detect
use
substrat
sigma
stop
n
h
absorb
nm
measur
use
elisa
plate
reader
tecan
zikv
ediiispecif
antibodi
mous
sera
test
use
elisa
describ
except
plate
coat
wildtyp
zikv
ediii
protein
follow
sequenti
incub
serial
dilut
mous
sera
hrpconjug
antimous
igg
thermo
fisher
scientif
competit
zikv
ediiispecif
human
mab
includ
mutant
ediiiinduc
mous
sera
bind
wildtyp
zikv
ediii
perform
use
elisa
describ
except
bind
wildtyp
ediii
mab
gml
test
presenc
serial
dilut
mous
sera
induc
zikv
ediii
vaccin
wild
type
mutant
pb
ediiimab
bind
measur
addit
hrpconjug
antihuman
iggfab
antibodi
subsequ
enzymat
reaction
zikv
plaqueform
assay
plaqu
reduct
neutral
test
zikv
human
strain
amplifi
vero
cell
determin
viral
titer
use
standard
plaqueform
assay
viral
titer
tissu
andor
sera
challeng
mice
detect
use
approach
zikv
titer
detect
around
mg
tissu
sampl
l
sera
detect
limit
pfug
tissu
pfuml
sera
plaqu
reduct
neutral
test
carri
measur
neutral
antibodi
titer
immun
mous
sera
activ
ediiispecif
mab
previous
describ
briefli
zikv
pfu
incub
pool
mous
sera
serial
dilut
quadrupl
dilut
mab
serial
dilut
gml
gml
quadrupl
dilut
h
follow
addit
antibodyviru
mixtur
vero
cell
incub
h
cell
overlaid
medium
carboxymethyl
cellulos
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
cultur
day
stain
crystal
violet
prnt
neutral
dose
nd
calcul
dilut
neutral
sera
mab
plaqu
reduct
use
calcusyn
comput
program
base
median
effect
principl
specif
prnt
nd
sera
mab
obtain
input
individu
dilut
neutral
valu
serum
mab
program
zikv
challeng
protect
evalu
zikv
challeng
experi
carri
previous
describ
briefli
day
postlast
immun
femal
balbc
mice
immun
zikv
ediii
wild
type
mutant
mate
respect
naiv
male
mice
within
strain
mice
inject
pb
includ
control
pregnant
femal
mice
intraperiton
ip
challeng
zikv
strain
pfu
mice
pfu
balbc
mice
lmous
zikv
titer
rna
copi
tissu
adult
mice
well
placenta
fetal
brain
collect
day
postinfect
detect
use
plaqueform
assay
describ
qrtpcr
describ
respect
separ
experi
male
mice
ip
challeng
zikv
pfu
day
postlast
immun
evalu
surviv
weight
anoth
day
ten
day
complet
challeng
experi
surviv
mice
wildtyp
mutant
zikv
ediii
group
challeng
zikv
pfu
observ
surviv
weight
describ
mice
bodi
weight
loss
human
euthan
passiv
protect
group
male
femal
mice
old
inject
ip
pool
sera
lmous
normal
equal
zikv
ediiispecif
igg
titer
dilut
pb
wildtypeor
mutantediiivaccineimmun
mice
collect
zikv
challeng
six
hour
later
mice
ip
challeng
zikv
strain
pfu
mice
inject
pbsinduc
mous
sera
includ
control
neutral
activ
passiv
transfer
mous
sera
detect
use
plaqu
reduct
neutral
test
zikv
titer
detect
sera
collect
day
day
postchalleng
use
zikv
plaqueform
assay
mous
surviv
weight
record
day
postchalleng
mice
bodi
weight
loss
human
euthan
qrtpcr
zikv
rna
copi
sera
tissu
challeng
mice
detect
use
qrtpcr
previous
describ
briefli
rna
extract
use
qiaamp
minelut
viru
spin
kit
sera
qiagen
rneasi
minikit
tissu
qiagen
quantifi
onestep
qrtpcr
use
power
sybr
green
pcr
master
mix
multiscrib
revers
transcriptas
ambion
rnase
inhibitor
thermo
fisher
scientif
viia
master
cycler
pcr
system
thermo
fisher
scientif
forward
revers
primer
amplif
standard
curv
qrtpcr
establish
serial
dilut
recombin
plasmid
contain
zikv
membran
e
gene
linear
standard
curv
rna
copi
correl
coeffici
r
valu
detect
limit
rna
copi
select
calcul
zikv
rna
sampl
zikv
rna
purifi
around
mg
tissu
sampl
detect
limit
rna
copiesg
tissu
statist
analysi
valu
present
mean
standard
error
mean
sem
statist
signific
antibodi
titer
among
differ
group
calcul
use
mannwhitney
test
statist
signific
viral
titer
among
differ
group
well
serum
inhibit
calcul
student
twotail
test
statist
signific
surviv
curv
among
differ
group
calcul
log
rank
test
use
graphpad
prism
statist
softwar
studi
support
nih
grant
intramur
fund
new
york
blood
center
zikv
strain
mab
obtain
bei
resourc
thank
dave
h
fremont
washington
univers
school
medicin
provid
mab
wt
yz
fl
ld
design
studi
wt
jc
gz
qg
lh
yc
conduct
experi
analyz
data
qg
fl
perform
structur
analysi
wt
yz
fl
ld
wrote
revis
proofread
paper
declar
compet
interest
